Lakefront Biotherapeutics NV
LKFT
$27.05
-$0.44-1.60%
NASDAQ
| 03/31/2026 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -98.17% | 25.66% | -736.89% | 148.66% | -42.04% |
| Total Depreciation and Amortization | -- | -- | -- | 304.77% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -849.54% | -66.45% | 202.98% | -231.25% | -482.87% |
| Change in Net Operating Assets | 100.91% | -221.76% | 187.03% | -33.58% | 53.56% |
| Cash from Operations | -71.88% | -203.88% | 25.56% | 19.81% | -95.54% |
| Capital Expenditure | 92.44% | 12.05% | 0.71% | -24.00% | 49.76% |
| Sale of Property, Plant, and Equipment | 236.39% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 42.40% | -174.97% | 1,894.78% | 124.43% | -- |
| Other Investing Activities | -20.88% | 88.18% | -14.76% | 6.86% | -61.45% |
| Cash from Investing | -16.52% | -4.93% | 31.57% | 17.19% | -60.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -25.93% | 40.65% | 36.97% | -47.43% | 1.93% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -24.14% | 35.99% | 33.46% | -42.95% | -2.50% |
| Foreign Exchange rate Adjustments | 151.23% | -43.13% | -197.53% | 365.15% | 155.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -188.70% | -189.56% | 254.54% | 150.29% | -935.93% |